NRK and neoplasm: In the past, NAMPT inhibitors (NAMPTi) showed modest anti-tumor activity mostly because NAMPT block was bypassed by compensation through other NAD-biosynthetic pathways, such as that regulated through NAPRT and NRK [41,42,43].